Journal of the Korean Orthopaedic Association (대한정형외과학회지)

Korean Orthopaedic Association (대한정형외과학회)
권호 표지
DOI QR코드

DOI QR Code

Opioids and Antidepressants for Pain Control in Musculoskeletal Disease

근골격계 질환에서 통증 조절을 위한 마약성 진통제 및 항우울제

  • Park, Se-Jin (Department of Orthopedic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Woo Sub (Department of Orthopedic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Jang, Taedong (Department of Orthopedic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 박세진 (성균관대학교 의과대학 강북삼성병원 정형외과학교실) ;
  • 김우섭 (성균관대학교 의과대학 강북삼성병원 정형외과학교실) ;
  • 장태동 (성균관대학교 의과대학 강북삼성병원 정형외과학교실)
  • Received : 2019.05.31
  • Accepted : 2019.10.23
  • Published : 2020.02.28
⟨ Previous Next ⟩

Abstract

The progression of aging and the increase in musculoskeletal diseases have led to an increase in invasive treatment methods, including various surgical methods, but conservative treatment should be attempted before surgical treatment in musculoskeletal diseases. Medication for pain control, such as acetaminophen, non-steroidal anti-inflammatory drugs, steroid, opioids, antidepressants, etc., is one of the most popular methods for pain control. If the pain receptors on peripheral organ are stimulated, pain is transmitted to the brain by the ascending pathway, and the brain then secretes endogenous opioids, such as endorphin, by the descending pathway for pain control. Opioids are substances that act on the opioid receptors, and there are three receptors for opioids. The affinity for each receptor varies according to the tissue and the patient's systemic status. Antidepressants work on the synapses in the central nervous system and its main mechanism is regulation of the ascending pathway. This is mainly effective in chronic pain and neuropathic pain, which is similar in effectiveness to opioids. This review focuses on the effectiveness, method of use, and side effects of opioids and antidepressants.

고령화의 진행 및 근골격계 질환의 증가로 인해 여러 가지 수술적 치료 방법을 포함한 침습적인 치료 방법이 증가되고 있으나 수술적 치료 시행 전 보존적 치료는 충분히 시행되어야 한다. 보존적 치료 중에서 통증 조절을 위한 약물 치료는 오래 전부터 보존적 치료의 가장 대표적인 치료 방법으로 사용되어 왔고 여전히 가장 흔히 사용되는 방법이다. 통증 조절을 위한 약물로는 아세트아미노펜(acetaminophen), 비스테로이드성 항염증제(non-steroidal anti-inflammatory drugs), 스테로이드(steroid), 마약성 진통제(opioid), 항우울제(antidepressants) 등이 있으며 저자는 마약성 진통제 및 항우울제에 대해서 살펴보고자 한다. 통증으로 인해 말초 부위에 있는 통각 수용체에 자극이 전달되면 통증은 중추 신경계로 전달되는 상향성 경로(ascending pathway)를 거쳐 대뇌에 전달되고 대뇌는 통증을 조절하기 위해 하향성 조절 경로(descending pathway)를 통해 엔도르핀(endorphin)과 같은 내인성 마약성 진통제를 분비하게 된다. 마약성 진통제라는 것은 마약성 진통제 수용체(receptor)에 작용하는 물질을 통틀어서 일컫는 말로 마약성 진통제는 세 가지의 수용체가 존재하며 조직이나 환자의 전신 상태에 따라서 각각의 수용체에 대한 친화성이 달라진다. 이와는 달리 항우울제는 중추신경계의 시냅스에 작용하여 통증을 조절하는 상향성 경로를 조절하는 것이 주된 기전으로 만성통증과 신경병성 통증에 효과적이며 이는 마약성 진통제 계열과 효과가 유사한 것으로 알려져 있다. 본 종설에서는 이러한 마약성 진통제와 항우울제의 효과적인 사용 방법, 사용 시 유의점 및 부작용 등에 대해 다루고자 한다.

Keywords

References

  1. Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum. 2012;64:2028-37. https://doi.org/10.1002/art.34347
  2. Podichetty VK, Mazanec DJ, Biscup RS. Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention. Postgrad Med J. 2003;79:627-33. https://doi.org/10.1136/pmj.79.937.627
  3. Tauben D. Nonopioid medications for pain. Phys Med Rehabil Clin N Am. 2015;26:219-48. https://doi.org/10.1016/j.pmr.2015.01.005
  4. Attal N, Cruccu G, Baron R, et al.; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-23,e67-88. https://doi.org/10.1111/j.1468-1331.2010.02999.x
  5. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol. 1995;15:615-35. https://doi.org/10.1007/BF02071128
  6. Megale RZ, Deveza LA, Blyth FM, et al. Efficacy and safety of oral and transdermal opioid analgesics for musculoskeletal pain in older adults: a systematic review of randomized, placebo-controlled trials. J Pain. 2018;19:475.e1-475.e24. https://doi.org/10.1016/j.jpain.2017.12.001
  7. Pasternak GW. Opioids and their receptors: are we there yet? Neuropharmacology. 2014;76 Pt B:198-203. https://doi.org/10.1016/j.neuropharm.2013.03.039
  8. Carnide N, Hogg-Johnson S, Cote P, et al. Early prescription opioid use for musculoskeletal disorders and work outcomes: a systematic review of the literature. Clin J Pain. 2017;33:647-58. https://doi.org/10.1097/AJP.0000000000000452
  9. Stein C, Hassan AH, Lehrberger K, Giefing J, Yassouridis A. Local analgesic effect of endogenous opioid peptides. Lancet. 1993;342:321-4. https://doi.org/10.1016/0140-6736(93)91471-W
  10. Stein C, Pfluger M, Yassouridis A, et al. No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. J Clin Invest. 1996;98:793-9. https://doi.org/10.1172/JCI118852
  11. Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T. Endorphin and enkephalin ameliorate excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol. 2001;28:2176-83.
  12. Spetea M. Opioid receptors and their ligands in the musculoskeletal system and relevance for pain control. Curr Pharm Des. 2013;19:7382-90. https://doi.org/10.2174/13816128113199990363
  13. Chou R, Fanciullo GJ, Fine PG, et al.; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-30. https://doi.org/10.1016/j.jpain.2008.10.008
  14. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain. 2007;129:355-62. https://doi.org/10.1016/j.pain.2007.02.014
  15. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573-82. https://doi.org/10.1016/j.jpain.2007.02.432
  16. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46. https://doi.org/10.1186/1472-6963-6-46
  17. Kastelic N, Farless H, Pericak A. Guidelines for the chronic use of opioid analgesics [Internet]. Euless (TX): The Federation of State Medical Boards; 2017 Apr [updated 2017 Aug 10; cited 2019 Jan 15]. Available from: http://sciencepolicy.duke.edu/content/guidelines-chronic-use-opioid-analgesics-model-policy.
  18. Hwang IC, Shim JY. Opioids use for chronic noncancer pain. J Korean Med Assoc. 2013;56:711-7. https://doi.org/10.5124/jkma.2013.56.8.711
  19. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589-94. https://doi.org/10.1503/cmaj.051528
  20. Lee YW. Opioid therapy for chronic nonmaliganat pain. Hanyang Med Rev. 2011;31:70-5. https://doi.org/10.7599/hmr.2011.31.2.70
  21. Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18:E2483. https://doi.org/10.3390/ijms18112483
  22. Barakat A, Hamdy MM, Elbadr MM. Uses of fluoxetine in nociceptive pain management: a literature overview. Eur J Pharmacol. 2018;829:12-25. https://doi.org/10.1016/j.ejphar.2018.03.042
  23. Onutu AH. Duloxetine, an antidepressant with analgesic properties - a preliminary analysis. Rom J Anaesth Intensive Care. 2015;22:123-8.
  24. Beal BR, Wallace MS. An overview of pharmacologic management of chronic pain. Med Clin North Am. 2016;100:65-79. https://doi.org/10.1016/j.mcna.2015.08.006
  25. Binder A, Baron R. The pharmacological therapy of chronic neuropathic pain. Dtsch Arztebl Int. 2016;113:616-25.
  26. Shah S, Kapoor S, Durkin B. Analgesic management of acute pain in the opioid-tolerant patient. Curr Opin Anaesthesiol. 2015;28:398-402. https://doi.org/10.1097/ACO.0000000000000218
  27. Acikalin A, Satar S, Avc A, Topal M, Kuvandk G, Sebe A. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther. 2010;17:30-3. https://doi.org/10.1097/MJT.0b013e318197eec6
  28. Jasiak NM, Bostwick JR. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014;48:1620-8. https://doi.org/10.1177/1060028014550645
  29. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75:e441-9. https://doi.org/10.4088/JCP.13r08672